EBOVAC1 Booster Studies - eboVAC PROJECT : eboVAC PROJECT

EBOVAC1 Booster Study for HIV+ adults

EBOVAC1 Booster study for HIV+ adults, EBL2010, is an open label study to evaluate the immune response to a booster dose of the Ad26.ZEBOV vaccine, administered to HIV positive participants in Kenya and Uganda. This study will include participants who previously received the 2-dose Ebola vaccine regimen (Ad26.ZEBOV and MVA-BN-Filo) in the EBL2002 vaccine trial. The booster dose is being given approximately four years after participants received dose 2.

The study consists of a screening period of up to 28 days to confirm eligibility of participants, followed by the booster vaccination and a 28-day post-booster vaccination follow-up period.

EBOVAC1 Booster study for children

EBOVAC1 Booster study for children, EBL2011, is an open label study to evaluate the immune response to a booster dose of the Ad26.ZEBOV vaccine administered to children. The study will include 50 children who previously received the 2-dose Ebola vaccine regimen (Ad26.ZEBOV and MVA-BN-Filo) in the EBOVAC-Salone trial.

Participants are aged between 4-11 years or 1-3 years, at the time of dose 1 vaccination. The study consists of a screening period of up to 28 days to confirm eligibility of participants, followed by the booster vaccination and a 28-day post-booster vaccination follow-up period.

These projects have received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861), EBOVAC3 (grant nr. 800176), EBOMAN (grant nr. 115850) and EBODAC (grant nr. 115847). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and European Federation of Pharmaceutical Industries and Associations (EFPIA).
www.imi.europa.eu